Sign In
Buy AVDL
$21.64
+0 (+0%)
At Close: May 08, 2026
Why Jazz Pharmaceuticals' Symphony of Growth Is About to End
12:10pm, Saturday, 09'th May 2020
Competition is about to ramp up significantly in the $1.7 billion market for treating chronic sleep disorder.
Jazz Pharmaceuticals (JAZZ) Q1 2020 Earnings Call Transcript
11:04am, Wednesday, 06'th May 2020
JAZZ earnings call for the period ending March 31, 2020.
Avadel Pharmaceuticals to Report First Quarter 2020 Financial Results on May 11th
08:05pm, Monday, 04'th May 2020
Avadel Pharmaceuticals plc (AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in pati
U.S. RESEARCH ROUNDUP-Berkshire Hathaway, DHT Holdings, Novo Nordisk
06:06pm, Monday, 04'th May 2020
Wall Street securities analysts revised their ratings and price targets on several
U.S.-listed companies, including Berkshire Hathaway, DHT Holdings and Novo Nordisk, on Monday.
HIGHLIGHTS
Bio Roundup: Remdesivir Data, Erasca’s $200M, a New FDA Nod & More
12:55pm, Friday, 01'st May 2020
Remdesivir, the investigational Gilead Sciences antiviral drug, looks more likely than ever to become the first treatment authorized by the FDA to treat
Avadel Pharmaceuticals Announces Pricing of Public Offering
12:28am, Wednesday, 29'th Apr 2020
Avadel Pharmaceuticals plc (AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in pati
6 Stocks To Watch: AMC, BLDR, CREX, KURA, NGL, RRGB
12:00am, Wednesday, 29'th Apr 2020
Stocks Analysis by Harry Boxer covering: MGM Resorts International, Fluor Corporation, Builders FirstSource Inc, Avadel Pharmaceuticals PLC. Read Harry Boxer's latest article on Investing.com
Is a Beat in Store for Avadel (AVDL) This Earnings Season?
04:55pm, Tuesday, 28'th Apr 2020
On Avadel's (AVDL) Q1 earnings call, investor focus will be on the company's lead candidate, FT218, currently being evaluated to treat excessive daytime sleepiness and cataplexy in narcolepsy patients
Can This Small-Cap Biotech Win a $1 Billion Market Opportunity for Narcolepsy?
02:48pm, Tuesday, 28'th Apr 2020
Will a small change in a drug's method of delivery be enough to generate over $1 billion in new sales?
The Daily Biotech Pulse: Pfizer Earnings, Roche's Spinal Muscular Dystrophy Treatment, Moderna COVID-19 Vaccine Update
11:36am, Tuesday, 28'th Apr 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 27) * AstraZeneca plc (NYSE: AZN) * Alnylam Pharmaceuti
Avadel Pharmaceuticals Announces Proposed Underwritten Public Offering
10:07pm, Monday, 27'th Apr 2020
Avadel Pharmaceuticals plc (AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in pati
This Top-Ranked Biotech Stock Touched A 4-Year High — Here's Why
08:20pm, Monday, 27'th Apr 2020
Avadel Pharmaceuticals stock rocketed Monday after the biotech company said its narcolepsy treatment succeeded in a Phase 3 test. The drug is a once-nightly form of sodium oxybate.
Why Avadel Pharmaceuticals Stock Is Crushing It Today
03:31pm, Monday, 27'th Apr 2020
Investors are excited about positive late-stage results for its narcolepsy drug.
A Look Into Avadel Pharmaceuticals' Price Over Earnings
02:38pm, Monday, 27'th Apr 2020
In the current session, Avadel Pharmaceuticals Inc. (NASDAQ: AVDL) is trading at $12.95, after a 31.74% increase. Over the past month, the stock increased by 63.60%, and in the past year, by 939.20%.
Morning Market Stats in 5 Minutes
02:33pm, Monday, 27'th Apr 2020
Movers Indices • S&P 500 ETF (NYSE:SPY) rose 0.78% to $285.09.• Nasdaq ETF (NASDAQ:QQQ) increased 1.06% to $216.10.• Dow Jones Industrial Average ETF (NYSE:DIA) increased 0.49% to $238.96.• FT
